Tau binding compounds
AssigneeVoyager Therapeutics, Inc.
InventorsTodd Carter, Jinzhao Hou, Vinodhbabu Kurella, Allan D. Capili, Wencheng Liu, Hiu Yan Chung, Jerrah Holth, Dillon Kavanagh, Maneesha Anand Paranjpe
Life of this patent
Estimating the term…
Abstract
The present disclosure provides anti-tau antibodies and vectorization thereof (e.g., into AAV particles). Also provided are methods of using anti-tau antibodies and/or AAV particles for prevention, treatment, and/or diagnosis of neurological indications.
Claims43
An antibody that binds to tau comprising a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (HC CDR1), an HC CDR2, and an HC CDR3, and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (LC CDR1), an LC CDR2, and an LC CDR3, wherein:
- (i) the HC CDR1 comprises the amino acid sequence, X1X2WMH wherein X1 is R or I;
- and X2 is Y or F, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 1184, and the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 410;
- and the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 1185, the LC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 1182, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 571;
- (ii) the HC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 1186, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 1187, and the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 1167;
- and the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 1188, the LC CDR2 comprises the amino acid sequence of RVS, and the LC CDR3 comprises the amino acid sequence of SEQ ID NOs:
- 571;
- or
- (iii) the HC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 1180, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 341, and the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 410;
- and the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 1181, the LC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 1182, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 571.
An antibody that binds to tau comprising a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (HC CDR1), an HC CDR2, and an HC CDR3, and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (LC CDR1), an LC CDR2, and an LC CDR3, wherein:
- (i) the HC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 1144, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 1145, and the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 410;
- and the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 1146, the LC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 529, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 571;
- (ii) the HC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 1165, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 1166, and the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 1167;
- and the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 473, the LC CDR2 comprises the amino acid sequence of RVS, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 571;
- or
- (iii) the HC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 314, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 341, and the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 410;
- and the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 1154, the LC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 529, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 571.
A nucleic acid encoding an antibody that binds to tau comprising a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (HC CDR1), an HC CDR2, and an HC CDR3, and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (LC CDR1), an LC CDR2, and an LC CDR3, wherein:
- (i) the HC CDR1 comprises the amino acid sequence of X1X2WMH wherein X1 is R or I;
- and X2 is Y or F, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 1184, and the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 410;
- and the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 1185, the LC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 1182, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 571;
- (ii) the HC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 1186, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 1187, and the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 1167;
- and the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 1188, the LC CDR2 comprises the amino acid sequence of RVS, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 571;
- or
- (iii) the HC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 1180, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 341, and the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 410;
- and the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 1181, the LC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 1182, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 571.
Dependencies are inferred from the claim text.